Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"New nasal therapies utilizing low cost, broad-spectrum molecules like NO are being
developed and other antiviral nasal sprays have also been shown to have anti-COVID-19
activity in clinical trials, including the mimetic antimicrobial peptide, brilacidin, and
astrodimer sodium [18,65,66]. Now is the time for conventional medicine and health
watchdogs like WHO to realize these sprays have the potential for global use, including
poorer counties, to reduce the burden of COVID-19 and thus the incidence of new
devastating variants and waves of disease".
One very important factor I think is cost saving which is very important to Medicare and could work in our favor. A pill formula vs Lecanemab outpatient infusion would save thousands of dollars per patient per year. Right now Medicare is struggling to keep costs under control and would welcome an effective prescription Alzheimer's treatment with open arms. Medicare premiums went up because of the high costs associated with Lecanemab.
That's it in a nutshell Pete. I think we see more good news in the combination anti fungal studies. "Following an in vitro drug screening of 1,402 compounds, Brilacidin showed promising antifungal activity and was subsequently selected for additional pre-clinical evaluation, including in combination with caspofungin (CAS), voriconazole (VOR), and posaconazole (POSA), all current antifungal treatments".
Many thanks for that recommendation. I see it's also on the Freevee app.
Looking forward to seeing what the final nasal formula looks like also more on the anti fungal. Happy Thanksgiving!
There is a world Antivirus conference in San Diego 28 NOVEMBER - 1 DECEMBER 2022.
https://www.terrapinn.com/conference/world-antiviral-congress/index.stm
The HHS Secretary who oversees the PREP Act (COVID-19 Emergency Declarations) specified it is to stay in place till October 1, 2024. Still plenty of time.
I don't believe the government has bought or owned a company outright either at least in modern day.. The instances of the US government owning a company was either by loan guarantee or shares owned such as with Chrysler.
This is bio-level3 research stuff where money is already allocated for these studies. Your confusing this with pet studies.
I should have inputted "rather then buying the company outright" the government would be more inclined to support development such as with BARDA. For one we have government funding through George Mason University now.
You would likely see the government supporting development then buying the company outright.
This could certainly be true of Dr. Missling. I've been invested/following this stock since 2015 and for what I remember he always waits till the morning of a conference before sending the press release. We shall see.
Something the average layperson/investor may not understand is the importance of releasing date to the scientific community in a respectful manner, it is not about shareholders. In true scientists, there is an implicit oath to further knowledge in a manner that would be most beneficial to humanity. Certain conferences are considered much more sacrosanct than others.
Hoping I caught the bottom this time. Looking forward to seeing PDD improvements correlating into the Alzheimer's study. But not only that..
Looking forward to more anti-fungal news! Seems a lot of need in that space. B as a topical would be good to see.
Yesterday-- Cramer said Anavex Life Sciences Corp "another one that I kind of like, I’ve got to tell you." However, he added, "I do not like losses in tech, but in biotech I can accept the fact that they have a good pipeline."
https://www.benzinga.com/trading-ideas/long-ideas/22/11/29720996/this-stock-is-up-106-in-2022-and-analysts-love-it-but-jim-cramer-says-theres-too-much-po
I never seen so much concern.lol Go B novel antifungal agent.
Thanks saw it here. Posted Nov. 15, 2022 7:30 AM ET
Source: Innovation Pharmaceuticals Inc
https://www.newmediawire.com/news
https://www.newmediawire.com/news/scientific-poster-on-innovation-pharmaceuticals-brilacidin-to-be-presented-at-2022-chemical-and-biological-defense-science-technology-conference-7059791
A lot companies on there.
Saw the drop was able to pick up another nice chunk in the $13.80 range. I'm not the only one who thinks we go much higher from here. Buying the dips.
I'm not even counting on the anti-viral any longer. Anti-fungal is a fairly clear field and may even be a better fit for B but we'll see. The question I have is what is Leo doing.
Market? I'm not even looking that far ahead. I'm hoping for more funding and a clinical trial plus caspofungin. Something to kick this tub in the rear.
https://newsfilter.io/a/7824559bc228d1a7b61ae5e5891ec970
10Q Interesting antifungal findings. Hopefully we have results that puts B in human studies.
"Antifungal - Recent data generated from independent researchers suggest Brilacidin has potential to be developed as a novel antifungal agent. Brilacidin converted caspofungin from a fungistatic into a fungicidal drug, enabling it to overcome both drug resistance and biofilm formation. Brilacidin exerted, to a lesser degree, synergistic effects with voriconazole in A. fumigatus. Further in vitro testing showed Brilacidin synergized with caspofungin in C. albicans, C. auris and C. neoformans. In an A. fumigatus immunosuppressed mouse model in invasive pulmonary aspergillosis, Brilacidin plus caspofungin cleared infection in the lungs by almost 95 percent, compared to ~50 percent when each compound was administered individually. Brilacidin also showed in vitro an additive inhibitory effect when combined with posaconazole in several species of Mucorales, the main etiological agents of mucormycosis, commonly referred to as black fungus. Brilacidin further showed potent in vitro stand-alone efficacy in C. neoformans, a major driver of illness in people living with HIV/AIDS".
Here's one you missed.Good info.
https://www.ipharminc.com/brilacidin-1
You first mood.
It must be the MM's are not executing trades. Other then that I don't know, I did see there was 35000 on the ask for .033
edit: 20.20k shares have now traded .032
If so, I look for pressure to be put on the FDA to curtail Biogen’s ridiculously expensive mab IV drug from Medicare. Since A-273 is a pill it would likely be listed as a formulary and much more likely for most insurances to cover.
Per wiki-" Broad-spectrum antivirals (BSAs) are a class of molecules or compounds, which inhibit the replication of a broad range of viruses (i.e. viruses belonging to two or more viral families)".
Lets hope this includes some cold and flu families. Go nasal B
George Mason University reported that several lines of evidence suggests brilacidin affects viral integrity and thus positioning itself as a broad-spectrum prophylactic countermeasure. If a nasal form of B is approved as a broad spectrum anti-viral we could also see it prescribed for seasonal colds and flu which would be a fantastic turn of events.
My thought is a phase2 human trial would be fully supported by government funding. All this pegs on current testing holding up. Hopefully stays positive.
Good point! A twofer.
Maybe it was the sushi. The principle investigator said none were related to brilacidin. I'm done with this. It's old news anyway.
I'm going by what the study reported. The DBSM reported no sae's related to B at an interim of the study. At the end of the study the principle investigator reported the 6 sae's reported ACROSS the study were NOT considered related to brilacidin.
"All Brilacidin treatment regimens were well tolerated. There were six severe adverse events (SAE) reported across the study, none of which were considered related to Brilacidin by the principal investigator".
Whether Dr Jorgensen now lives in a nicer home has yet to be mentioned.
Agree Pete. In comparing the phase2b study Dr Jorgensen stated that B as a single dose was comparable to daptomycin's 7 day regimen so clearly B has a strong anti-bacterial quality. Looking forward to hearing more on the ant-fungal results.
“We worked with the FDA in designing the recent phase 2b study,” said Dr. Jorgensen. ” As predicted, a lower total dose of Brilacidin, given as a single-dose regimen, was well tolerated and efficacy was comparable to that of the 7-day regimen of the active control, daptomycin.”
“It’s important to note that a single-dose regimen has benefits beyond safety and efficacy,” Dr. Jorgensen added. ”It can maximize patient compliance and thereby reduce the potential for the development of antibiotic resistance. Of course, Brilacidin’s unique mechanism of action to penetrate the bacterial cell wall to eradicate bacteria is another reason why resistance is unlikely to develop. Further, Brilacidin has anti-inflammatory and anti-biofilm properties. When considering all these factors, Brilacidin has the potential to transform the way we treat infectious diseases.”
I'm fairly sure the address www.chemist-4-u.com has more to do with the adds not the article. Hope the following is accurate but who knows.
"New antiviral drug, developed by novartis and molecular partners, built to resist viral mutations and variants. Nirmatrelvir, ritonavir, remdesivir and molnupiravir are antiviral medicines".
"Brilacidin has been granted u.s. New antiviral drug, developed by novartis and molecular partners, built to resist viral mutations and variants".
Todays pr is just an update on BeaMed. BRL updates regarding anti-viral and anti-fungal come as lab news is released. Like you I want to see the nasal formulation finished.
Pr read 70million patient pool so possibly $20k goes to machine use per treatment. Adds up to some real money.
I wonder what is the future plan here, if they say it works and get approval is BeaMed going build a company around it or simply sell and license it out?
First of all not many bio's make it to the big time. If I thought B was useless I would have run to the nearest exit. I happen to believe we still have a shot so I stay in. I will be watching 2023 carefully.
I think this is a good space for IPIX to be in. Looking for more on this-
"Following an in vitro drug screening of 1,402 compounds, Brilacidin showed promising antifungal activity and was subsequently selected for additional pre-clinical evaluation, including in combination with caspofungin (CAS), voriconazole (VOR), and posaconazole (POSA), all current antifungal treatments".
“It is a remarkable feature of Brilacidin that it can potentiate multiple antifungals, in different pathogenic fungi, including hard-to-treat species. New antifungal combination strategies are urgently needed due to a scarcity of novel agents, alongside emerging resistance in the clinical setting,” commented Gustavo Henrique Goldman, Professor of Molecular Biology, University of São Paulo, Brazil, and a Chief Editor for Frontiers in Fungal Biology, a peer-reviewed journal dedicated to the study of mycology.
Maybe betting news won't come out til day of CTAD. Time to cover ~5 weeks.
I see hub made it so you can even give yourself a pat on the back. Thumbs Up style!!